“We were given the opportunity to engage with Genentech in 1977, two years before its IPO [initial public offering], and we ...

Developing new medications can take years. But computational biologist Aviv Regev says AI-powered cell mapping is ...

Genentech, a member of the Roche Group, has announced that it is voluntarily withdrawing the US indication of Tecentriq (atezolizumab) for the treatment of adult patients with certain types of ...

Roche’s subsidiary Genentech has shared positive Phase III data with the US Food and Drug Administration (FDA) as the company ...

About Genentech in neuroscience Neuroscience is a major focus of research and development at Genentech and Roche. Our goal is to pursue groundbreaking science to develop new treatments that help ...

Screening tests are critical in early detection because they can find cancer before symptoms appear, when treatment is more ...

Genentech announced that new data were presented at the AD/PD 2025 International Conference on Alzheimer’s and Parkinson’s Diseases in Vienna, Austria. Highlights included presentations from the ...

Aviv Regev, executive vice president and head of Genentech Research & Early Development (gRED) NVIDIA’s push into the life sciences sector has been rewarded by a wide-ranging deal with Roche’s ...

The company has a long history of leading HR policy changes. Now it is kowtowing to the president's anti-DEI stand.

But biotechnology leader Genentech, in part through its Advancing Inclusive Research® initiative, is striving to change that. Alongside industry stakeholders, the organization is testing new ...

--(BUSINESS WIRE)-- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the Phase III MUSETTE trial comparing a high dose of Ocrevus ® (ocrelizumab ...